TRDAEntrada Therapeutics, Inc.
Entrada Therapeutics, Inc. (TRDA) sells experimental therapies for rare genetic disorders, primarily targeting Duchenne muscular dystrophy (DMD). The next catalyst is Nov 11, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to deliver on its clinical roadmap and manage cash burn amid a crowded and capital-intensive therapeutic space .
- TRDA has reported $5.34M in revenue for the period ending June 30, 2026, but continues to operate at a steep net loss.
- Free cash flow remains negative, and the company has struggled with consistent revenue growth, down 87.9% YoY.
- The firm’s path to profitability hinges on the success of its Phase 1/2 trials for ENTR-601, with limited near-term commercialization prospects.
The Read
3% following FDA catalysts, with mixed reactions to clinical data and earnings, often driven by positive updates on drug development and competitive landscape shifts.
The schedule
- Thu8Oct
Crucial make-or-break clinical data for the higher dose cohort of the ENTR-601-44 Phase 1/2 study in DMD.
- Wed11Nov
The earnings report will test whether the company can deliver a positive surprise on revenue and guidance, following a recent regulatory setback. The last earnings print showed a bearish outcome due to cash flow concerns.
- Wed20Jan
Assessment of President Trump's administration policies regarding FDA oversight, clinical trial design flexibility, and biotech funding allocations.
- Sun14Feb
This report will test the company's ability to show progress in clinical trials and secure additional funding. The last earnings print was bearish due to a lack of clarity on trial timelines.
- Thu6May
The report will assess the company's ability to maintain cash flow and secure regulatory approvals. The last earnings print was bearish due to a cash burn issue.
- Wed11Aug
This report will test the company's ability to deliver on its long-term growth strategy, including new product launches and partnerships. The last earnings print was bearish due to a lack of strategic clarity.
Past
- Wed12Aug
Actual outcome: Bear · $6.40 at outcome
TRDA reported earnings in line with expectations, but the stock fell 16.6% as guidance signaled continued cash burn and limited near-term growth prospects. The lack of clarity on capital allocation and the deteriorating cash position overshadowed the neutral earnings report, pushing the stock below the bear floor. The outcome aligns with the bear case as the market reacted to the lack of progress in addressing the company's financial challenges.
Quarterly earnings report with extreme focus on capital allocation, given the severe cash burn profile against dwindling reserves.
- Mon20Jul
Actual outcome: Bull · $7.46 at outcome
Competitor regulatory updates in the Duchenne muscular dystrophy (DMD) space favorably altered the competitive landscape for Entrada. These developments highlighted the differentiation and potential advantages of Entrada's platform, driving a 17.7% rally as investors gained confidence in its relative valuation and pipeline prospects.
Expected readout or regulatory update from competitors in the heavily contested DMD space, which will heavily influence Entrada's relative platform valuation.
- Thu7May
Actual outcome: Mixed · $6.83 at outcome
Entrada Therapeutics reported topline results from Cohort 1 of its Phase 1/2 study for ENTR-601-44, highlighting favorable safety and early functional improvements in Duchenne muscular dystrophy patients. Despite the positive clinical updates, the trial data and a Q1 earnings miss initially triggered a sharp selloff. However, the stock ultimately stabilized and recovered to close completely flat by the outcome date, resulting in a mixed overall reaction.
Clinical milestone readout for ENTR-601 coupled with the high probability of a follow-on equity financing event.
- Thu7May
Actual outcome: Bear · $6.83 at outcome
Entrada Therapeutics experienced a brutal stock selloff, driving shares well below the bear floor, following the release of its Phase 1/2 ELEVATE-44-201 clinical trial data for Duchenne muscular dystrophy. Although the company reported favorable safety and early functional improvements alongside an in-line Q1 earnings report, the market reacted negatively to observations of lower plasma exposure in Cohort 1 participants.
Q1 2026 results and management’s commentary on cash runway and potential capital raises will frame dilution risk; reaffirmed runway into key 2027 data with no near-term financing could support shares around $14.00, while a pulled-forward equity raise or shorter runway could drag the stock toward $14.00.
- Wed6May
Actual outcome: Bull · $7.32 at outcome
Entrada Therapeutics announced topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study for Duchenne muscular dystrophy. Despite reporting favorable safety and early functional improvement, the clinical data underwhelmed investors and sparked a brutal selloff, which was further
Expected timeline for TRDA to file a new IND or provide an expanded dataset demonstrating the broader utility of its EEV platform.
- Wed15Apr
Actual outcome: Bear · $12.72 at outcome
Ahead of the event, Entrada reached a 52-week high following an Oppenheimer upgrade and a price target increase to $23.00. However, shares subsequently reversed course and plummeted to $6.84 by the run date, falling well below the $8.50 bear floor. This severe decline indicates that the highly anticipated ENTR-601 clinical data failed to meet market expectations, undermining confidence in the EEV platform and triggering a decisively bearish sell-off.
Initial clinical data from ENTR-601 in Duchenne muscular dystrophy could re-rate Entrada as a leading DMD genetic medicine player, with strong efficacy and safety potentially driving the stock toward $18.00, while inconclusive or negative data could undermine the EEV platform and push shares down toward $18.00.
- Thu26Feb
Actual outcome: Bull · $12.50 at outcome
Entrada met EPS estimates and provided positive clinical updates, including an Independent Data Monitoring Committee recommendation to increase the dosage in the ELEVATE-44-201 study. Management's confirmation of multiple data catalysts for 2026 and a stable cash runway addressed previous concerns regarding high burn rates, supporting the stock's climb to $12.70 by the run date.
The focus will be on the high cash burn rate from Q3 2025 and the resulting short cash runway. Management commentary or lack thereof regarding immediate financing/milestone payments will drive the price.
